Expert Review of Clinical Immunology最新文献_第5页

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort. 在真实世界的泛癌症队列中，抗pd -1治疗的季节性时机和生存结果。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-04 DOI: 10.1080/1744666X.2026.2682180

Haydar C Yuksel, Caner Acar, Gokhan Sahin, Pınar Açar, Sercan On, Burcak Ş Karaca

{"title":"Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.","authors":"Haydar C Yuksel, Caner Acar, Gokhan Sahin, Pınar Açar, Sercan On, Burcak Ş Karaca","doi":"10.1080/1744666X.2026.2682180","DOIUrl":"10.1080/1744666X.2026.2682180","url":null,"abstract":"Background: Circannual variation in immune function may influence the efficacy of immune checkpoint inhibitors (ICIs), yet clinical evidence regarding seasonal effects remains limited.Methods: We retrospectively analyzed adults with metastatic solid tumors treated with anti-PD-1 monotherapy at a single center between 2015 and 2024. Seasons were defined by regional daylight patterns: summer (April-October) and winter (November-March). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier estimates, log-rank tests, multivariable Cox regression, propensity score matching (PSM), and a 3-month landmark analysis were performed.Results: Among 430 patients, 245 (57.0%) initiated ICIs in summer and 185 (43.0%) in winter. In the unmatched cohort, summer initiation was associated with longer PFS and OS. After PSM, 181 patients remained in each group, and the survival advantage persisted: median PFS was 6.2 versus 3.6 months (HR 0.72, 95% CI 0.56-0.91) and median OS was 21.5 versus 12.4 months (HR 0.74, 95% CI 0.58-0.94) for summer versus winter, respectively. Landmark and multivariable analyses confirmed these findings.Conclusions: Initiation of anti-PD-1 therapy during summer was associated with significantly improved survival, suggesting that seasonal modulation of host immunity may influence ICI outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"703-713"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug therapies and immune pathways in ocular manifestations of inflammatory skin diseases. 炎症性皮肤病眼部表现的药物治疗和免疫途径。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-18 DOI: 10.1080/1744666X.2026.2682188

Wei Ren Tan, Ryan J Liew, Carlos Cifuentes-González, Alejandra de-la-Torre, Akimichi Morita, Alexander A Navarini, Rupesh Agrawal, Hazel H Oon

{"title":"Drug therapies and immune pathways in ocular manifestations of inflammatory skin diseases.","authors":"Wei Ren Tan, Ryan J Liew, Carlos Cifuentes-González, Alejandra de-la-Torre, Akimichi Morita, Alexander A Navarini, Rupesh Agrawal, Hazel H Oon","doi":"10.1080/1744666X.2026.2682188","DOIUrl":"10.1080/1744666X.2026.2682188","url":null,"abstract":"Introduction: Inflammatory skin diseases and ocular disorders frequently coexist due to shared embryological origins, overlapping immune pathways, and common barrier functions. The increasing use of targeted systemic therapies in dermatology has further highlighted the skin-eye interface, introducing both therapeutic benefits and iatrogenic ocular complications.Areas covered: This review outlines the shared embryological and immunological mechanisms linking the skin and ocular surface, with emphasis on major inflammatory pathways, including TNF-α, Th17, and JAK-STAT signaling. We summarize the prevalence and spectrum of ocular involvement across common inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, pemphigus vulgaris, and ocular mucous membrane pemphigoid. In addition, we evaluate ocular adverse effects associated with commonly used dermatologic therapies, highlighting the emerging phenomenon of iatrogenic and paradoxical inflammation.Expert opinion: Ocular manifestations arising from both disease-associated and iatrogenic etiologies remain underrecognized in clinical practice. Early recognition, interdisciplinary collaboration, and risk-adapted strategies, including care accessibility and patient education, are essential to prevent vision-threatening complications. A shift from reactive care to proactive, risk-stratified screening based on individual patient risk profiles can improve clinical outcomes across the skin-eye axis.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"591-611"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium. 测量青少年系统性硬化症的疾病活动性：来自汉堡2024研讨会的多学科共识。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-22 DOI: 10.1080/1744666X.2026.2685050

Ivan Foeldvari, Kathryn S Torok, Jens Klotsche, Jonathan C Li, Cosimo Bruni, Patricia Costa-Reis, Maurizio Cutolo, Christopher P Denton, Kim Fligelstone, Francesco Del Galdo, Clara Giménez-Roca, Jörg Henes, Ozgur Kasapcopur, Suzanne C Li, Edoardo Marrani, Catherine H Orteu, John D Pauling, Clarissa Pilkington, Laura Ross, Dieneke Schonenberg-Meinema, Daniel E Furst, Vanessa Smith

{"title":"Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.","authors":"Ivan Foeldvari, Kathryn S Torok, Jens Klotsche, Jonathan C Li, Cosimo Bruni, Patricia Costa-Reis, Maurizio Cutolo, Christopher P Denton, Kim Fligelstone, Francesco Del Galdo, Clara Giménez-Roca, Jörg Henes, Ozgur Kasapcopur, Suzanne C Li, Edoardo Marrani, Catherine H Orteu, John D Pauling, Clarissa Pilkington, Laura Ross, Dieneke Schonenberg-Meinema, Daniel E Furst, Vanessa Smith","doi":"10.1080/1744666X.2026.2685050","DOIUrl":"10.1080/1744666X.2026.2685050","url":null,"abstract":"Introduction: Assessment of disease activity in juvenile systemic sclerosis (jSSc) is essential for clinical care and trial readiness, yet no validated pediatric activity measures exist. Adult systemic sclerosis activity tools, including the Scleroderma Clinical Trials Consortium Activity Index, revised CRISS, and revised EUSTAR, provide conceptual frameworks but require adaptation for developmental, physiologic, and feasibility considerations for children. At the 17th Hamburg Symposium on JSSc, an international multidisciplinary panel reviewed adult indices, evaluated corresponding variables in the jSSc Inception Cohort and the NRCOS registry, and conducted a structured Delphi process to define organ-specific indicators of clinically meaningful activity in jSSc.Areas covered: Across skin, pulmonary, cardiac, vascular, musculoskeletal, gastrointestinal, renal, and global domains, the panel reached broad and often unanimous consensus on variables reflecting active, potentially reversible disease. Key endorsed measures included mRSS progression, new ILD on HRCT, ≥10% declines in FVC or DLCO, new cardiac abnormalities, active digital ulcers, synovitis, myositis, nutritional decline, and physician global assessment. Patient-reported outcomes were strongly supported across domains.Expert opinion: These consensus-derived indicators provide the first comprehensive pediatric-specific foundation for defining disease activity in jSSc and represent a critical step toward developing and validating a unified pediatric activity index suitable for future clinical trials.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"645-660"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148175768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Keratoconus: an ocular manifestation of systemic immune dysregulation? 圆锥角膜：一种全身免疫失调的眼部表现？

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-05-29 DOI: 10.1080/1744666X.2026.2682176

Burhan Başkan, Yusuf Evcimen

{"title":"Keratoconus: an ocular manifestation of systemic immune dysregulation?","authors":"Burhan Başkan, Yusuf Evcimen","doi":"10.1080/1744666X.2026.2682176","DOIUrl":"10.1080/1744666X.2026.2682176","url":null,"abstract":"Background: Keratoconus is a corneal ectatic disorder traditionally considered non-inflammatory, but emerging evidence suggests immune system involvement. This study evaluates the epidemiological relationship between keratoconus and immune-mediated diseases in the Eastern Anatolian population.Research design and methods: In this retrospective cohort study, 642 patients diagnosed with keratoconus (2017-2025) and 2568 age-sex-matched controls were examined. Prevalence of rheumatoid arthritis, ulcerative colitis, Crohn's disease, Hashimoto's thyroiditis, autoimmune hepatitis, asthma, allergic rhinitis, and atopic dermatitis was compared. Logistic regression adjusted for age, sex, BMI, and smoking status. Bonferroni correction (p < 0.00625) and sensitivity analyses were applied.Results: Any immune-mediated disease was present in 38.6% of keratoconus patients versus 21.2% of controls (p < 0.001). After Bonferroni correction, significant associations remained for rheumatoid arthritis (aOR = 7.89, p = 0.003), asthma (aOR = 2.32, p < 0.001), allergic rhinitis (aOR = 1.58, p = 0.001), and autoimmune hepatitis (aOR = 6.12, p = 0.006). Immune disease prevalence increased with keratoconus severity.Conclusions: Strong epidemiological associations exist between keratoconus and several immune-mediated diseases, suggesting immunological mechanisms may play a role in pathogenesis. However, findings demonstrate associations rather than causality, and some associations did not withstand correction for multiple comparisons. Prospective validation is needed.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"715-722"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Use of leflunomide for the management of ocular mucous membrane pemphigoid: a multicentric retrospective cohort study. 使用来氟米特治疗眼粘膜类天疱疮：一项多中心回顾性队列研究。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-05-31 DOI: 10.1080/1744666X.2026.2682193

Ariana Ringer, Andrea Smichowski, Ana Rosa Perez, María Lorena Brance, Ignacio Javier Gandino, Ramiro Adrian Gomez

{"title":"Use of leflunomide for the management of ocular mucous membrane pemphigoid: a multicentric retrospective cohort study.","authors":"Ariana Ringer, Andrea Smichowski, Ana Rosa Perez, María Lorena Brance, Ignacio Javier Gandino, Ramiro Adrian Gomez","doi":"10.1080/1744666X.2026.2682193","DOIUrl":"10.1080/1744666X.2026.2682193","url":null,"abstract":"Background: Ocular mucous membrane pemphigoid (OcMMP) is a chronic autoimmune scarring disease that may lead to progressive visual impairment. Evidence regarding the use of leflunomide (LFN) in OcMMP is limited.Research design and methods: We conducted a retrospective, observational multicenter study including adult patients with OcMMP treated with LFN between May 2006 and June 2025 at rheumatology centers in Argentina. Clinical characteristics, treatment regimens, and outcomes were collected from medical records. Disease severity and progression were assessed using Foster staging. LFN was used as second-line therapy after methotrexate failure, as monotherapy or in combination. Treatment effectiveness at 6 months was defined as suppression of ocular inflammation and achievement of a glucocorticoid-sparing effect. Treatment failure included persistent inflammation, discontinuation due to adverse events, lack of steroid-sparing effect, or need for additional immunomodulatory therapy.Results: Thirty-six patients (mean age 67.1 years) were included. At 6 months, 61.1% achieved inflammatory control with glucocorticoid reduction or discontinuation; overall effectiveness during follow-up was 55.5%. Foster stage progression occurred in 8.5%. Adverse events leading to discontinuation were infrequent.Conclusions: LFN may be a safe and effective option for selected OcMMP patients, although the retrospective design and limited sample size warrant prospective studies.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"697-702"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sarcoid-like reactions: a comprehensive review of granulomatous diseases mimicking sarcoidosis. 结节样反应：模拟结节病的肉芽肿性疾病的综合综述。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-07 DOI: 10.1080/1744666X.2026.2682185

Andrea Giovanni Ledda, Martina Ceraudo, Klara Radovic, Giulia Costanzo, Cinzia Milito, Davide Firinu, Francesco Cinetto

{"title":"Sarcoid-like reactions: a comprehensive review of granulomatous diseases mimicking sarcoidosis.","authors":"Andrea Giovanni Ledda, Martina Ceraudo, Klara Radovic, Giulia Costanzo, Cinzia Milito, Davide Firinu, Francesco Cinetto","doi":"10.1080/1744666X.2026.2682185","DOIUrl":"10.1080/1744666X.2026.2682185","url":null,"abstract":"Introduction: Sarcoid-like reactions (SLR) are granulomatous conditions characterized by non-caseating epithelioid cell granulomas that mimic sarcoidosis but arise in patients who do not fulfill diagnostic criteria for systemic sarcoidosis. The overlap with sarcoidosis poses a significant challenge, as misdiagnosis can lead to inappropriate treatment.Areas covered: We performed a comprehensive review of the available literature summarizing SLRs associated with malignancies, infections, and most relevant drugs involved, discussing the timing of onset, patterns of organ involvement, and prognostic implications. Management strategies are discussed according to the underlying trigger, ranging from simple observation to corticosteroids or targeted immunosuppression, and from pathogen-directed therapy to careful continuation or modification of anticancer treatment.Expert opinion: SLRs represent a diagnostic and pathogenetic challenge due to the plasticity of the granulomatous immune response, which can be triggered by drugs, malignancy, or other stimuli, often mimicking systemic sarcoidosis. Dedicated studies are needed to develop standardized diagnostic criteria and algorithms that integrate clinical, histological, and immunological features to accurately distinguish SLRs from sarcoidosis and guide management.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"631-643"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the impact of malaria infection on immune memory of a clinical concern? 疟疾感染对免疫记忆的影响是临床关注的问题吗？

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-14 DOI: 10.1080/1744666X.2026.2688976

Katsuyuki Yui, Maria Lourdes Macalinao, Julius Hafalla

引用次数: 0

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis. 靶向细胞因子风暴：治疗小儿噬血细胞淋巴组织细胞增多症的新疗法。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-06-01 Epub Date: 2026-06-23 DOI: 10.1080/1744666X.2026.2691043

Hilary Cahill, Robert F Wynn, Srividhya Senthil

{"title":"Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.","authors":"Hilary Cahill, Robert F Wynn, Srividhya Senthil","doi":"10.1080/1744666X.2026.2691043","DOIUrl":"10.1080/1744666X.2026.2691043","url":null,"abstract":"Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal disorder characterized by immune hyper-activation and subsequent tissue and organ infiltration by proinflammatory cytokines. Primary HLH is caused by underlying genetic mutations in key genes responsible for cellular cytotoxicity, whereas secondary HLH is driven by infection, malignancy, and autoimmune disease as the underlying trigger for immune activation. Chemotherapy-based treatments for pediatric HLH have improved survival and outcomes for patients, however, there is a significant unmet need in the development of targeted therapies to limit drug toxicity and further improve overall survival.Areas covered: We review primary and secondary HLH, current treatment strategies, and present rationale and available evidence for emerging targeted therapies for this orphan disease, including the human monoclonal anti-IFN‑γ antibody emapalumab, the anti-CD52 monoclonal antibody alemtuzumab, and the JAK1/2 inhibitor ruxolitinib, in the treatment of pediatric HLH.Expert opinion: Development of targeted therapies in pediatric HLH is critical to improve survival and overall outcomes for these patients. Emapalumab, alemtuzumab, and ruxolitinib show promising results, however, widespread use is limited by small, non-randomized trials in a heterogenous population. Further international collaborative efforts to develop clinical trials that compare conventional chemotherapy treatments head-to-head with these newer therapies are critical for advancement of these agents.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"661-677"},"PeriodicalIF":4.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A framework for translational research in interstitial lung disease (ILD) using bronchoalveolar lavage (BAL). 间质性肺疾病（ILD）应用支气管肺泡灌洗（bal）的转化研究框架。

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-06-07 DOI: 10.1080/1744666X.2026.2675640

Connar M A Mawer, Stefan C Stanel, Emily M Ward, David J F Smith, Rebecca C Hull, Puja Mehta

{"title":"A framework for translational research in interstitial lung disease (ILD) using bronchoalveolar lavage (BAL).","authors":"Connar M A Mawer, Stefan C Stanel, Emily M Ward, David J F Smith, Rebecca C Hull, Puja Mehta","doi":"10.1080/1744666X.2026.2675640","DOIUrl":"10.1080/1744666X.2026.2675640","url":null,"abstract":"Introduction: Bronchoalveolar lavage (BAL) offers a minimally invasive window into the distal airspaces and is an important tool in the study of interstitial lung disease (ILD). As chest imaging has obviated the need for diagnostic surgical biopsies, research tissue is increasingly limited, strengthening the rationale for BAL. By sampling the epithelial lining fluid, BAL captures cellular and acellular host- and microbe-derived signals relevant to inflammation and fibrogenesis, enabling multi-omic mechanistic and biomarker studies. However, variation in technique, dilution, and pre-analytical handling limits reproducibility and cross-center comparability.Areas covered: Here, we summarize key biological insights gained from BAL fluid-based studies, divided into cellular, acellular and microbiome compartments. We highlight current guidance, methodological challenges, and outline standardized frameworks to maximize translational scientific yield and multi-center validation.Expert opinion: Standardized protocols will maximize the value of BAL samples. Paired multi-compartment analysis can expand actionable readouts: multimodal cellular pipelines combining single-cell RNA and protein profiling, aligned with clinical annotation, may define ILD endotypes and prognostic/predictive biomarkers. Acellular BALF bioassays coupled to transcriptional and proteomic signatures can support mechanistic validation and pharmacological targeting, while microbiome profiling integrated with host multi-omics may improve risk stratification. Ultimately, these data could inform clinical decision-making and regulatory endpoints.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"499-517"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases. 皮肤病学中的胰高血糖素样肽-1受体激动剂（GLP-1RAs）：炎症性皮肤病的皮肤不良事件和新出现的疗效

IF 4 3区医学

Expert Review of Clinical Immunology Pub Date : 2026-05-01 Epub Date: 2026-04-30 DOI: 10.1080/1744666X.2026.2665732

Meng Jie Ho, Choon Fong Liew, Nguan Soon Tan, Akimichi Morita, Hazel H Oon

{"title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases.","authors":"Meng Jie Ho, Choon Fong Liew, Nguan Soon Tan, Akimichi Morita, Hazel H Oon","doi":"10.1080/1744666X.2026.2665732","DOIUrl":"10.1080/1744666X.2026.2665732","url":null,"abstract":"Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and next-generation incretin therapies are increasingly used for diabetes and obesity, yet cutaneous adverse events remain incompletely characterized. New-onset dermatological manifestations after GLP-1RA initiation such as rash or alopecia may be misattributed to baseline inflammatory skin disease rather than drug-induced toxicity.Areas covered: Searches of PubMed, Embase and Cochrane from inception to 4 October 2025 yielded 3,006 records; 80 primary studies were included. Small studies suggest improvement in psoriasis and hidradenitis, particularly with liraglutide. Reported cutaneous events include hypersensitivity reactions, panniculitis, bullous pemphigoid, lupus, vasculitis, and alopecia or appearance-related changes. Dermatologic data for investigational incretin-based agents remain sparse overall.Expert opinion: Most cutaneous adverse reactions are mild to moderate, manageable and reversible; however, underreporting and inconsistent terminology limit accurate risk estimation. Emerging evidence suggests GLP-1RAs may improve psoriasis and hidradenitis via weight-dependent and anti-inflammatory mechanisms, supporting adjunctive use in selected patients. CTCAE-aligned grading, photo-supported documentation and early dermatology input could guide 'continue vs pause vs stop' decision-making, improving diagnostic confidence and enabling prospective drug safety surveillance. Future directions include mechanistic studies dissecting weight-independent pathways and prospective trials to identify optimal patient phenotypes for GLP-1RA therapy in inflammatory skin diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"445-462"},"PeriodicalIF":4.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0